Objective: The objective of this study was to identify whether compounding oral suspensions with SyrSpend SF based on tablets or capsules is a suitable alternative for using raw pharmaceutical materials. Methods: Suspensions based on 5 different tablets and capsules were studied in SyrSpend SF. The summary of product characteristics of these different tablets and capsules were obtained from the manufacturer. Our hypothesis was that, if the maximum beyond-use date of the study was reached, the excipient did not seem to have an influence on the stability of the active pharmaceutical ingredient (API) within the studied time frame. Results: All excipients used in flecainide acetate, labetalol HCl, and tiagabine HCl tablets as well as in celecoxib and oseltamivir capsules did not seem to influence the beyond-use date of the overall suspension based on SyrSpend SF. Conclusion: Although using raw materials as API sources is preferred, oral suspensions with SyrSpend SF prepared from crushed tablets or opened capsules could be a possible alternative. Based on this study, a wide range of different excipients does not seem to impact the beyond-use date of different APIs compounded in SyrSpend SF.
Community and hospital pharmacists are often required to compound extemporaneous oral liquids in case of patients with dose adjustments, for patients unable to swallow oral solid medication or when patients are receiving their medication via an enteral feeding tube. 1 To assure patient safety and compliance, a number of aspects need to be considered, including chemical, physical, and microbiological stability and palatability of the compounded medication.
In practice, due to convenience or availability of raw pharmaceutical ingredients, (hospital) pharmacists often resort to capsules or tablets as the source of their active pharmaceutical ingredient (API). These commercial solid dosage forms are formulated with-among others-excipients promoting dilution, flow and disintegration, colorants, flavors, and binding agents. 2 Stability of the oral liquid is therefore no longer just determined by the interaction of the API with the vehicle alone, but also by the chemical and physical interaction of the API with the excipients. 1, 3 As formulation of oral liquids is often only partially supported by pharmacopoeia and other scientific evidence, assigning a beyond-use date (BUD) by the (hospital) pharmacist can be challenging.
A wide range of APIs is currently being studied in SyrSpend SF, a commercial oral suspension base. Compatibility results with SyrSpend SF have been published for more than 70 different APIs. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] In all of these studies, the compatibility was assessed by measuring the percentage recovery at varying time points throughout a 90-day period at controlled room and/or at controlled refrigerated temperature. The majority of the compatibility studies have been performed with raw pharmaceutical APIs. In case of celecoxib, flecainide acetate, labetalol hydrochloride, oseltamivir phosphate, and tiagabine hydrochloride where no raw pharmaceutical material was available, commercially available tablets or capsules were used. High-performance liquid chromatography with diode array detection was used for both the compatibility study and a forced degradation study. The latter was executed with the aim of identifying all degradation products that may be produced during storage of the samples. All APIs except for 717393H PXXXX10.1177/0018578717717393Hospital PharmacyDijkers et al.
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1 Fagron, Rotterdam, The Netherlands 2 Universidad San Jorge, Villanueva de Gállego Zaragoza, Spain oseltamivir phosphate were analyzed with the HP Agilent Series 1100; oseltamivir phosphate was studied using a Varian Prostar. Analytical grade chemical reagent and standards were used throughout the study. During validation of the method, linearity, fit, limit of detection (LOD), limit of quantification (LOQ), and recovery were determined. In the compatibility study, the appropriate amount of API was levigated with SyrSpend SF PH4 (liquid) using geometric dilution to form a smooth suspension. The API concentration was determined in 6-fold at predefined time points until T = 90 days. The oral liquid formulation was considered stable when the content was between 90% and 110% of the declared amount.
Although the compatibility studies were set up to determine the BUD of the APIs, we believe that the results can also be used to determine a possible influence of the excipients on the API. We postulated that the presence of excipients either accelerate API degradation or have no influence on API stability. Therefore, if the API in the study reaches the maximal studied BUD, the excipient does not seem to have an influence on the stability of the API within the studied time frame. For the study, Celecoxib (Celebrex) 200 mg capsules were obtained from Pfizer, flecainide acetate (Apocard) 100 mg tablets were obtained from Meda Pharma SAU, labetalol hydrochloride (Trandate) 200 mg tablets were obtained from Kern Pharma, oseltamivir phosphate (Tamiflu) 75 mg capsules were obtained from Roche, and tiagabine hydrochloride (Gabitril) 15 mg oral tablets were obtained from Teva Pharma BV. The list of excipients present in these oral dosage forms were acquired from the manufacturer's summary of product characteristics. [22] [23] [24] [25] [26] [27] The results of the compatibility studies are summarized in Table 1 . The compatibility data show that all of the actives reached a BUD of 90 days, 4, 28 indicating no influence of the excipients present in the tested celecoxib, flecainide acetate, labetalol hydrochloride, oseltamivir phosphate, or tiagabine hydrochloride tablets or capsules.
These results found in SyrSpend SF are in concordance with the results found in published compatibility studies with other vehicles, although in general these APIs show a longer BUD when combined with SyrSpend SF than with the other vehicles (simple syrup, fruit juices, or water). These data are summarized in Table 2 . The oseltamivir phosphate results in SyrSpend SF 4 were published at an intermediate time point (30 days) because of the bird flu epidemic at that time. Consecutive study results have shown a 90 days BUD. 29 Summarizing, the data of previously performed compatibility studies indicates that commonly used excipients present in crushed tablets or opened capsules appear to have no distinct influence on the stability of celecoxib, flecainide acetate, labetalol hydrochloride, oseltamivir phosphate, and tiagabine hydrochloride when compounded in SyrSpend SF. This indicates that tablets and capsules could be a possible API source, when no raw pharmaceutical material is available. From this study, it can be concluded that a wide range of different excipients does not seem to impact the maximum BUD of different APIs compounded in SyrSpend SF. 
